AVEO Pharmaceuticals Earnings: Here’s Why Investors are Not Happy Now
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 10.77%.
AVEO Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.49 in the quarter versus EPS of $-0.58 in the year-earlier quarter.
Revenue: Rose 1311.82% to $15.53 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: AVEO Pharmaceuticals, Inc. reported adjusted EPS loss of $-0.49 per share. By that measure, the company beat the mean analyst estimate of $-0.77. It beat the average revenue estimate of $14.49 million.
Quoting Management: “We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO-1, receiving the FDA’s acceptance of the NDA submission and expanding tivozanib clinical development into patients with triple negative breast cancer,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “On the heels of our recent financing, we are continuing to build out our commercial infrastructure and remain focused on preparing for the potential launch of tivozanib in advanced RCC in the second half of 2013.”
Key Stats (on next page)…
Revenue increased 1422.55% from $1.02 million in the previous quarter. EPS increased to $-0.49 in the quarter versus EPS of $-0.69 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.47 to a loss $0.53. For the current year, the average estimate has moved up from a loss of $2.96 to a loss of $2.91 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)